Methylpropyltryptamine (MPT), also known as N-methyl-N-propyltryptamine, is a psychedelic drug of the tryptamine family. It is a homologue of methylethyltryptamine (MET).
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin described MPT's effects as being unknown and its dose as being greater than 50mg orally.
An analytical method for MPT's detection has been reported.
In 2019, Chadeayne et al. published the crystal structure of MPT. The authors describe the structure as "...a single molecule in the asymmetric unit, with an indole group that demonstrates a mean deviation from planarity of 0.015 Að."
Analogues of MPT include 4-HO-MPT, 5-MeO-MPT, methylethyltryptamine (MET), ethylpropyltryptamine (EPT), ethylisopropyltryptamine (EiPT), and dipropyltryptamine (DPT), among others.
MPT is not a controlled substance in Canada as of 2025.
MPT is not an explicitly controlled substance in the United States. However, it is an isomer of diethyltryptamine (DET), which is a schedule I controlled substance in this country, and so may be considered a controlled substance in the United States similarly.